New agents in clinical trials in acute myeloid leukemia (AML).
| Class . | Agent . | Target . |
|---|---|---|
| Abbreviations: MDR, multidrug resistance inhibitor; P-gp, P-glycoprotein; FT, farnesyltransferase; A, cytarabine; FLT3 ITD, fms-like tyrosine kinase 3 internal tandem duplication; SAHA, suberoylanilide hydroxamic acid; VEGF, vascular endothelial growth factor | ||
| Antibodies/Immunoconjugates | Gemtuzumab ozogamicin | CD33 |
| MDR inhibitors | PSC833, Zosuquidar | P-gp |
| FT inhibitors | Tipifarnib (Zarnestra) | Lamin A, HJJ-2 Rho B, CENP-E and CENP-F, lamins A and B |
| FLT3 inhibitors | PKC-412, CEP-701, MLN518, SU11248 | FLT3 ITD |
| Histone deacetylase cytarabine (HDAC) inhibitors | Valproic acid, SAHA, depsipeptide | HDAC |
| Antiangiogenic agents | Bevacizumab | VEGF |
| Apoptosis inhibitors | Genasense | BCL-2 |
| Deoxyadenosine analogs | Clofarabine | DNA |
| Class . | Agent . | Target . |
|---|---|---|
| Abbreviations: MDR, multidrug resistance inhibitor; P-gp, P-glycoprotein; FT, farnesyltransferase; A, cytarabine; FLT3 ITD, fms-like tyrosine kinase 3 internal tandem duplication; SAHA, suberoylanilide hydroxamic acid; VEGF, vascular endothelial growth factor | ||
| Antibodies/Immunoconjugates | Gemtuzumab ozogamicin | CD33 |
| MDR inhibitors | PSC833, Zosuquidar | P-gp |
| FT inhibitors | Tipifarnib (Zarnestra) | Lamin A, HJJ-2 Rho B, CENP-E and CENP-F, lamins A and B |
| FLT3 inhibitors | PKC-412, CEP-701, MLN518, SU11248 | FLT3 ITD |
| Histone deacetylase cytarabine (HDAC) inhibitors | Valproic acid, SAHA, depsipeptide | HDAC |
| Antiangiogenic agents | Bevacizumab | VEGF |
| Apoptosis inhibitors | Genasense | BCL-2 |
| Deoxyadenosine analogs | Clofarabine | DNA |